SML2419
GSK690
≥98% (HPLC)
同義詞:
(R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-(p-tolyl)pyridin-3-yl) benzonitrile), (R)-4-(5-(Pyrrolidin-3-ylmethoxy)-2-p-tolylpyridin-3-yl)benzonitrile, 4-(2-(4-Methylphenyl)-5-((3R)-3-pyrrolidinylmethoxy)-3-pyridinyl)benzonitrile, GSK 354, GSK 690, GSK-354, GSK-690, GSK354
登入查看組織和合約定價
全部照片(1)
About This Item
推薦產品
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
2-8°C
SMILES 字串
N#CC1=CC=C(C2=CC(OC[C@H]3CNCC3)=CN=C2C4=CC=C(C)C=C4)C=C1
InChI
1S/C24H23N3O/c1-17-2-6-21(7-3-17)24-23(20-8-4-18(13-25)5-9-20)12-22(15-27-24)28-16-19-10-11-26-14-19/h2-9,12,15,19,26H,10-11,14,16H2,1H3/t19-/m1/s1
InChI 密鑰
IQVDLEXWAPYWDT-LJQANCHMSA-N
生化／生理作用
GSK690 (GSK354) is a cell-permeable pyrrolidinylmethoxypyridine-based compound that inhibits lysine-specific demethylase 1 (LSD1; KDM1A) in a potent and reversible manner (IC50 = 90 nM) without affecting MAO-A activity (IC50 >200 μM). GSK690 is shown to induce the expressions of CD86 (EC50 = 1.4 μM in THP1 cells) and LY96 (EC50 = 423 nM in MV4-11 cells), and prevent adipogenesis in murine preadipocyte cultures.
Potent and reversible lysine-specific demethylase LSD1 (KDM1A) inhibitor that induces CD86 and LY96 expression and prevents adipogenesis.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
Daniel P Mould et al.
Journal of medicinal chemistry, 60(19), 7984-7999 (2017-09-12)
Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML). Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clinical trials; however, the development of effective
Alba Maiques-Diaz et al.
Cell reports, 22(13), 3641-3659 (2018-03-29)
Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leukemia (AML) with MLL translocations. The assumption has been that differentiation is induced through blockade of LSD1's histone demethylase activity. However, we observed that rapid, extensive, drug-induced changes in transcription occurred
Tinka Haydn et al.
Cell death & disease, 8(6), e2879-e2879 (2017-06-16)
The lysine-specific demethylase 1 (LSD1) is overexpressed in several cancers including rhabdomyosarcoma (RMS). However, little is yet known about whether or not LSD1 may serve as therapeutic target in RMS. We therefore investigated the potential of LSD1 inhibitors alone or
Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments
Hitchin JR, Blagg J, Burke R .
Medicinal Chemistry, 1513-1522 (2013)
John P McGrath et al.
Cancer research, 76(7), 1975-1988 (2016-02-04)
Lysine-specific demethylase 1 (KDM1A) is a transcriptional coregulator that can function in both the activation and repression of gene expression, depending upon context. KDM1A plays an important role in hematopoiesis and was identified as a dependency factor in leukemia stem
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務